Article
Respiratory System
David B. Price, William Henley, Jose Eduardo Delfini Cancado, Leonardo M. Fabbri, Huib A. M. Kerstjens, Alberto Papi, Nicolas Roche, Elif Sen, Dave Singh, Claus F. Vogelmeier, Sara Barille, Elena Nudo, Victoria Carter, Derek Skinner, Rebecca Vella, George Georges
Summary: This study compared the risk of developing pneumonia in new users of inhaled corticosteroids (ICS) for COPD. The findings showed that commencing a formulation containing fluticasone was associated with an increased risk of pneumonia compared to extrafine beclomethasone.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(2022)
Article
Cardiac & Cardiovascular Systems
A. Renner, K. Marth, R. Breyer-Kohansal, W. Pohl
Summary: Five non-interventional studies from Austria evaluated the real-world effectiveness and tolerability of an extrafine fixed dose beclomethasone/formoterol treatment for partially or non-controlled asthma patients. The treatment showed significant improvements in asthma control, lung function, and symptom scores, with high tolerability and patient satisfaction.
RESPIRATORY MEDICINE
(2023)
Article
Medicine, General & Internal
William B. B. Feldman, Jerry Avorn, Aaron S. S. Kesselheim, Joshua J. J. Gagne
Summary: Clinical guidelines recommend LAMA-LABA therapy over ICS-LABA therapy for COPD, but conflicting data from randomized trials have raised concerns. This cohort study found that LAMA-LABA therapy was associated with reduced COPD exacerbations and pneumonia hospitalizations compared to ICS-LABA therapy, suggesting it should be preferred for COPD patients.
JAMA INTERNAL MEDICINE
(2023)
Review
Medicine, General & Internal
Xiao-Jian Zhou, Zhen Qin, Jiao Lu, Jian-Guo Hong
Summary: This study compared the safety and efficacy of salmeterol/fluticasone (SFC) vs. montelukast (MON) or combination of montelukast and fluticasone (MFC) in children and adolescents with bronchial asthma. The results indicated that SFC may be more effective than MFC, especially in improving asthma control level.
CHINESE MEDICAL JOURNAL
(2021)
Article
Respiratory System
Gwen S. Skloot, Alessandro Guasconi, Benjamin R. Lavon, George Georges, Wilfried De Backer, Dmitry Galkin, Mauro Cortellini, Ilaria Panni, Jason H. T. Bates
Summary: This study investigated the effects of switching therapy from non-extrafine high-dose inhaled corticosteroid/long-acting beta(2)-agonist to extrafine medium-dose beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium in patients with symptomatic chronic obstructive pulmonary disease. Functional Respiratory Imaging was used to assess airway geometry and lung function.
RESPIRATORY RESEARCH
(2023)
Review
Respiratory System
Robert A. Wise, Mona Bafadhel, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M. G. Halpin, MeiLan K. Han, Peter Lange, David A. Lipson, Fernando J. Martinez, Diego J. Maselli, Dawn Midwinter, Dave Singh, Maeva Zysman, Mark T. Dransfield, Richard E. K. Russell
Summary: This review discusses methodological differences in defining and recording pneumonia events in clinical trials of ICS use in COPD, as well as factors contributing to varying pneumonia incidence. Variations in diagnosis criteria and reporting methods across trials were found to influence the reported pneumonia rates.
EUROPEAN RESPIRATORY REVIEW
(2021)
Review
Pharmacology & Pharmacy
Young-A Heo
Summary: Budesonide/glycopyrronium/formoterol is an inhaled fixed-dose combination approved for the maintenance treatment of COPD, effectively reducing exacerbations and improving lung function in patients with inadequately controlled disease.
Article
Chemistry, Medicinal
Mohammad H. Alyami, Eman Zmaily Dahmash, Dalia Khalil Ali, Hamad S. Alyami, Hussien AbdulKarim, Samar A. Alsudir
Summary: This study presents a one-step approach for the synthesis of nanoaggregates made from a biocompatible and biodegradable polyamide based on L-lysine amino acid, using market-leading active pharmaceutical ingredients for the management of asthma. The produced nanocapsules displayed excellent aerosol performance and drug release, outperforming the marketed product in terms of fine particle fraction and emitted dose.
Review
Medicine, Research & Experimental
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Ji-Hee Youn, Mia Malmenas, Nancy A. Risebrough, Jatin Agarwal, Maria Nassim, Raj Sharma, Chris Compton, Claus F. Vogelmeier, MeiLan K. Han, David M. G. Halpin
Summary: This network meta-analysis suggests that single-inhaler triple therapy with FF/UMEC/VI may be more effective in treating COPD compared to other triple and dual therapies. It improves forced expiratory volume, reduces exacerbation rates, improves quality of life, and decreases rescue medication use.
ADVANCES IN THERAPY
(2022)
Article
Chemistry, Multidisciplinary
Zbigniew Doniec, Magdalena Olszanecka-Glinianowicz, Piotr Hantulik, Agnieszka Almgren-Rachtan, Jerzy Chudek
Summary: This study aimed to prove the efficacy and safety of Easyhaler (R) in COPD patients, and the results showed that it significantly improved the quality of life and dyspnea symptoms in COPD patients. The patients expressed high satisfaction with the product, and the adherence rate exceeded 90%.
APPLIED SCIENCES-BASEL
(2022)
Review
Respiratory System
Delphine Vauterin, Frauke Van Vaerenbergh, Anna Vanoverschelde, Jennifer K. Quint, Katia Verhamme, Lies Lahousse
Summary: This article systematically reviews the existing methods for assessing adherence to COPD medication in healthcare databases and evaluates the reporting of influencing variables. The study finds significant variations in adherence assessment methods and recommends attention to transparency and reporting of variables.
EUROPEAN RESPIRATORY REVIEW
(2023)
Article
Cardiac & Cardiovascular Systems
Martina Orlovic, Tiziana Magni, Vasily Lukyanov, Ines Guerra, Alessandra Madoni
Summary: In patients with uncontrolled asthma, the addition of BDP/FF/G is a cost-effective maintenance therapy option compared to BDP/FF. High-dose BDP/FF/G is even more cost-effective than BDP/FF + tiotropium, as it is both cheaper and improves quality-adjusted life-years (QALYs).
RESPIRATORY MEDICINE
(2022)
Review
Multidisciplinary Sciences
Ting Liu, Dan Yang, Chuntao Liu
Summary: The study compared the clinical effects of extrafine HFA-BDP-F and nonextrafine ICS-LABA in treating asthma, finding no significant differences in improving pulmonary function, controlling asthma symptoms, reducing exacerbations, and improving lung deposition.
Review
Medicine, General & Internal
Kayleigh M. Kew, Ella Flemyng, Bradley S. Quon, Clarus Leung
Summary: This article compares the clinical effectiveness and safety of increased versus stable doses of inhaled corticosteroids (ICS) for home management of asthma exacerbations. The results suggest that increasing the dose does not have a significant impact on reducing the need for oral steroids, but other clinically important benefits and potential harms cannot be ruled out due to limitations in the trials.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Health Care Sciences & Services
Paschalis Steiropoulos, Stavros Tryfon, Christos Kyriakopoulos, Konstantinos Bartziokas, Konstantinos Kostikas
Summary: The study found that COPD patients treated with SFC via the Elpenhaler® device showed significant improvement in lung function and dyspnea at 6 and 12 months, irrespective of the presence of comorbidities.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Critical Care Medicine
Peter M. A. Calverley, Fernando J. Martinez, Jorgen Vestbo, Christine R. Jenkins, Robert Wise, David A. Lipson, Nicholas J. Cowans, Julie Yates, Courtney Crim, Bartolome R. Celli
Summary: Countries participating in COPD trials consistently differ in reporting exacerbations, which may explain why large studies are needed to show differences in exacerbation risk reduction between treatments.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Letter
Respiratory System
Jorgen Vestbo, Grant Waterer, David Leather, Courtney Crim, Nawar Diar Bakerly, Lucy Frith, Loretta Jacques, Catherine Harvey, Imran Satia, Ashley Woodcock
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Yunus Colak, Borge G. Nordestgaard, Jorgen Vestbo, Shoaib Afzal, Peter Lange
Summary: Targeted spirometry in a general population setting can detect undiagnosed cases of COPD. A significant proportion of individuals with undiagnosed COPD also have other treatable conditions, such as smoking, respiratory symptoms, low physical activity, hypertension, hypercholesterolemia, and diabetes.
RESPIRATORY MEDICINE
(2022)
Correction
Medicine, Research & Experimental
Dave Singh, Gabriel Garcia, Kittipong Maneechotesuwan, Peter Daley-Yates, Elvis Irusen, Bhumika Aggarwal, Isabelle Boucot, Norbert Berend
ADVANCES IN THERAPY
(2022)
Article
Critical Care Medicine
Dave Singh, Alvar Agusti, Fernando J. Martinez, Alberto Papi, Ian D. Pavord, Jadwiga A. Wedzicha, Claus F. Vogelmeier, David M. G. Halpin
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Respiratory System
Philip J. Thompson, Gerard J. Criner, Mark T. Dransfield, David M. G. Halpin, MeiLan K. Han, David A. Lipson, Ghassan J. Maghzal, Fernando J. Martinez, Dawn Midwinter, Dave Singh, Lee Tombs, Robert A. Wise
Summary: This study explores the relationship between chronic mucus hypersecretion (CMH) and treatment response. The results show that FF/UMEC/VI treatment has similar improvements in health status and lung function, regardless of CMH status. However, in CMH patients, FF/UMEC/VI has a better effect on exacerbation relief compared to other treatments.
Article
Critical Care Medicine
Tessa M. Kole, Elise Vanden Berghe, Monica Kraft, Judith M. Vonk, Martijn C. Nawijn, Salman Siddiqui, Kai Sun, Leonardo M. Fabbri, Klaus F. Rabe, Kian Fan Chung, Gabriele Nicolini, Alberto Papi, Chris Brightling, Dave Singh, Thys van der Molen, Sven-Erik Dahlen, Alvar Agusti, Rosa Faner, Jadwiga A. Wedzicha, Gavin C. Donaldson, Ian M. Adcock, Lies Lahousse, Huib A. M. Kerstjens, Maarten van den Berge
Summary: This post-hoc analysis investigates the determinants, clinical implications, and outcome of persistent airflow limitation (PAL) in patients with asthma. The study reveals that PAL is not only present in severe asthma, but also in a considerable proportion of patients with milder disease. In patients with mild asthma, PAL is associated with eosinophilic inflammation and a higher risk of exacerbations, suggesting the need for increased treatment intensity.
LANCET RESPIRATORY MEDICINE
(2023)
Editorial Material
Medicine, Research & Experimental
Christian Domingo, Dave Singh
Summary: Short-acting beta(2) agonists (SABAs) have been commonly used for asthma treatment since the 1950s. However, poor adherence to regular inhaled corticosteroid (ICS)-based maintenance therapy often leads to excessive use of SABAs and negative outcomes. Current treatment guidelines lack consensus on the use of SABAs, and some suggest using ICS-formoterol as an alternative reliever therapy. This article examines the pharmacology and current use of SABAs, discusses the importance of regular ICS dosing, and evaluates the evidence supporting changes in reliever treatment recommendations.
ADVANCES IN THERAPY
(2023)
Article
Respiratory System
Efthymia Papadopoulou, Jan Hansel, Zsofia Lazar, Konstantinos Kostikas, Stavros Tryfon, Jurgen Vestbo, Alexander G. Mathioudakis
Summary: This meta-analysis explored the safety and effectiveness of mucolytics as an add-on treatment for COPD exacerbations. The analysis included 24 RCTs involving 2192 patients and showed that mucolytics can increase treatment success rate, improve symptom scores, reduce persistent cough, and facilitate expectoration. There is also some evidence suggesting that mucolytics may reduce future exacerbation risk and improve quality of life.
EUROPEAN RESPIRATORY REVIEW
(2023)
Editorial Material
Critical Care Medicine
Dave Singh
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Editorial Material
Respiratory System
Bartolome Celli, Jorgen Vestbo
EUROPEAN RESPIRATORY JOURNAL
(2023)
Letter
Respiratory System
Jorgen Vestbo, Kare Press-Kristensen
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Ema Rastoder, Pradeesh Sivapalan, Josefin Ekloef, Imane Achir Alispahic, Alexander Svorre Jordan, Christian B. Laursen, Jorgen Vestbo, Christine Jenkins, Rune Nielsen, Per Bakke, Gustavo Fernandez-Romero, Daniel Modin, Niklas Johansen, Filip Soeskov Davidovski, Tor Biering-Sorensen, Jorn Carlsen, Jens Ulrik Staehr Jensen
Summary: This study compared the efficacy of amlodipine and bendroflumethiazide in treating hypertension in patients with chronic obstructive pulmonary disease (COPD). The results showed that amlodipine use was associated with a reduced risk of death, but had no significant effect on the risk of acute severe exacerbations or hospital admissions.
Article
Biochemistry & Molecular Biology
Peter Kamstrup, Ema Rastoder, Pernille Hogh Hellmann, Pradeesh Sivapalan, Emil List Larsen, Jorgen Vestbo, Charlotte Suppli Ulrik, Jens P. Goetze, Filip Krag Knop, Jens Ulrik Staehr Jensen
Summary: Synthetic corticosteroids are commonly used for their anti-inflammatory and immunosuppressant effects, although their association with venous thromboembolism remains unclear. A trial was conducted to investigate the effects of prednisolone on haemostasis in healthy men. The results showed that prednisolone did not affect clot formation but influenced certain prothrombotic markers and antithrombotic markers.
Article
Respiratory System
Claire Bradley, Panos Alexandris, David R. Baldwin, Richard Booton, Mike Darby, Claire J. Eckert, Rhian Gabe, Neil Hancock, Sam Janes, Martyn Kennedy, Jason Lindop, Richard D. Neal, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Jorgen Vestbo, Philip A. J. Crosbie, Matthew E. J. Callister
Summary: Spirometry offered alongside LDCT screening can potentially identify cases of undiagnosed and misdiagnosed COPD. Future research should assess the downstream impact of these findings and determine the impact of co-delivering spirometry on other parameters of LDCT screening.
